These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
215 related articles for article (PubMed ID: 7946002)
1. A risk-benefit assessment of carvedilol in the treatment of cardiovascular disorders. Louis WJ; Krum H; Conway EL Drug Saf; 1994 Aug; 11(2):86-93. PubMed ID: 7946002 [TBL] [Abstract][Full Text] [Related]
2. Carvedilol. A reappraisal of its pharmacological properties and therapeutic use in cardiovascular disorders. Dunn CJ; Lea AP; Wagstaff AJ Drugs; 1997 Jul; 54(1):161-85. PubMed ID: 9211087 [TBL] [Abstract][Full Text] [Related]
3. Pharmacology of carvedilol: rationale for use in hypertension, coronary artery disease, and congestive heart failure. Ruffolo RR; Feuerstein GZ Cardiovasc Drugs Ther; 1997 May; 11 Suppl 1():247-56. PubMed ID: 9211017 [TBL] [Abstract][Full Text] [Related]
4. Carvedilol. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy. McTavish D; Campoli-Richards D; Sorkin EM Drugs; 1993 Feb; 45(2):232-58. PubMed ID: 7681374 [TBL] [Abstract][Full Text] [Related]
5. Use of carvedilol in hypertension: an update. Leonetti G; Egan CG Vasc Health Risk Manag; 2012; 8():307-22. PubMed ID: 22661898 [TBL] [Abstract][Full Text] [Related]
6. Results of therapy with carvedilol, a beta-blocker vasodilator with antioxidant properties, in hypertensive patients. Moser M; Frishman W Am J Hypertens; 1998 Jan; 11(1 Pt 2):15S-22S. PubMed ID: 9503102 [TBL] [Abstract][Full Text] [Related]
7. Sympathetic activation and the role of beta-blockers in chronic heart failure. Krum H Aust N Z J Med; 1999 Jun; 29(3):418-27. PubMed ID: 10868514 [TBL] [Abstract][Full Text] [Related]
8. Carvedilol, a novel vasodilating beta-blocker with the potential for cardiovascular organ protection. Feuerstein GZ; Ruffolo RR Eur Heart J; 1996 Apr; 17 Suppl B():24-9. PubMed ID: 8733068 [TBL] [Abstract][Full Text] [Related]
13. [Balanced beta--alpha-blocker treatment with carvedilol in mild-moderate arterial hypertension]. Perocchio M; Gigli G; Barra M; Sacchetti R; Vallebona A; Rosolen GA; Orlandi S Minerva Cardioangiol; 1996 Mar; 44(3):115-21. PubMed ID: 8767610 [TBL] [Abstract][Full Text] [Related]
14. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group. Packer M; Bristow MR; Cohn JN; Colucci WS; Fowler MB; Gilbert EM; Shusterman NH N Engl J Med; 1996 May; 334(21):1349-55. PubMed ID: 8614419 [TBL] [Abstract][Full Text] [Related]
16. Carvedilol and the kidney. Dupont AG Clin Investig; 1992; 70 Suppl 1():S127-31. PubMed ID: 1350479 [TBL] [Abstract][Full Text] [Related]
17. Treatment of chronic stable angina with carvedilol: a multiple-action neurohormonal antagonist. A review of controlled clinical trials. González Maqueda I J Int Med Res; 1998; 26(3):107-19. PubMed ID: 9718465 [TBL] [Abstract][Full Text] [Related]
18. Carvedilol: a review of its use in chronic heart failure. Keating GM; Jarvis B Drugs; 2003; 63(16):1697-741. PubMed ID: 12904089 [TBL] [Abstract][Full Text] [Related]
19. The use of carvedilol in elderly hypertensive patients. Morgan TO; Anderson A; Cripps J; Adam W Eur J Clin Pharmacol; 1990; 38 Suppl 2():S129-33. PubMed ID: 1974503 [TBL] [Abstract][Full Text] [Related]
20. Hypotension with dobutamine: beta-adrenergic antagonist selectivity at low doses of carvedilol. Lindenfeld J; Lowes BD; Bristow MR Ann Pharmacother; 1999 Dec; 33(12):1266-9. PubMed ID: 10630826 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]